Gan & Lee’s Ondibta Receives Positive CHMP Opinion – EU Biosimilar Pathway Opened
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced that the European Medicines Agency (EMA) has...
Sanofi
Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP
Sanofi (NASDAQ: SNY) announced that its anti‑vWF Nanobody Cablivi (caplacizumab for injection) received formal marketing...
Sanofi Q3 2025 Results: 7 % Revenue Growth, Dupixent Drives Pharma Upswing
Sanofi (NASDAQ: SNY) today reported its third‑quarter 2025 financial performance, posting a 7 % year‑on‑year increase...
Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation
Sanofi (NASDAQ: SNY) announced today a new capital infusion of USD 625 million into its corporate venture...
Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes
French pharmaceutical giant Sanofi (NASDAQ: SNY) today announced that its investigational drug Tzield (teplizumab) has...
Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP
The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi’s (NASDAQ: SNY) Wayrilz...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for IgG4-Related Disease by EMA
French pharmaceutical major Sanofi (NASDAQ: SNY) announced that it has received another orphan drug designation...
Sanofi’s SAR446523 Gains FDA Orphan Drug Status for Relapsed or Refractory Multiple Myeloma
French pharmaceutical major Sanofi (NASDAQ: SNY) reported that the U.S. Food and Drug Administration (FDA)...
Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma
France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...
Sanofi to Acquire Vicebio Ltd for Up to USD 1.6 Billion, Advancing Next-Gen Vaccine Development
Vicebio Ltd has entered into an exclusive, definitive agreement to be acquired by France-based major...
Sarepta Therapeutics Announces 500 Employee Layoffs After FDA Elevidys Trial Suspension
US-based Sarepta Therapeutics, a subsidiary of Sanofi (NASDAQ: SNY), announced the layoff of approximately 500...
Esteve to Acquire Sanofi’s Caprelsa Rights in Over 50 Countries for Medullary Thyroid Cancer Treatment
Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set...
Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
France-based major Sanofi (NASDAQ: SNY) has secured Orphan Drug Designation (ODD) from the US Food...
Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development
US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....
Bio-Thera Partners with SteinCares for Biosimilar Commercialization in Latin America
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) and Costa Rica-based SteinCares have entered into a licensing...
Sanofi’s Sarclisa Recommended for EU Approval in Newly Diagnosed Multiple Myeloma
France major Sanofi (NASDAQ: SNY) announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...
Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment
France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...
Sanofi and Abu Dhabi Department of Health Collaborate to Accelerate Vaccine Development
France major Sanofi (NASDAQ: SNY) this week signed a Memorandum of Understanding (MoU) with the...
Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial
French pharmaceutical giant Sanofi (NASDAQ: SNY) announced positive results from a Phase II study of...